Endo Pharmaceuticals Gets a Thumbs Down and 4 More Analyst Downgrades to Know
Stock upgrades and downgrades are a controversial part of Wall Street. Despite regulations, many banks and firms still have a positive bias toward current clients and companies desired as future clients. In addition, Wall Street analysts are straight-up biased to the buy side. The percentage of sell recommendations is normally below 15 percent!
Regardless, upgrades and downgrades move stocks in the short-term. They fall into our CHEAT SHEET framework category ‘C = Catalyst for a Stock?s Movement’. Here are catalysts you must know today:
Endo Pharmaceuticals (NASDAQ:ENDP): Standpoint Research downgraded its rating on this company from Buy to Hold.
Expeditors International (NASDAQ:EXPD): Goldman Sachs downgraded its rating on this company from Conviction-Buy to Buy.
France Telecom SA (NYSE:FTE): Goldman Sachs downgraded its rating on this company from Sell to Conviction Sell.
Health Management Associates (NYSE:HMA): Deutsche Bank downgraded its rating on this company from Buy to Hold and changed its price target to $13.00.
InterDigital (NASDAQ:IDCC): William Blair downgraded its rating on this company from Outperform to Market Perform.
Investing Insights: Will Pfizer Continue This Bullish Run?